

PRODUCT INFORMATION



ACTRIIB Extracellular Domain (human, recombinant)


Item No. 44184

Overview and Properties

Synonyms:	Activin RIIB, Activin Receptor Type IIB, Activin Receptor Type-2B, ACTR-IIB, ACVR2B, AVR2B
Source:	Active recombinant human C-terminal His-tagged ACTRIIB extracellular domain expressed in HEK293 cells
Amino Acids:	19-134
Uniprot No.:	Q13705
Molecular Weight:	15 kDa
Storage:	-80°C (as supplied)
Stability:	≥1 year
Purity:	≥97% estimated by SDS-PAGE
Supplied in:	Lyophilized from sterile PBS, pH 7.4
Endotoxin Testing:	<1.0 EU/μg, determined by the LAL endotoxin assay


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images




Lane 1: MW Markers
Lane 2: ACTRIIB Extracellular Domain

SDS-PAGE Analysis of ACTRIIB Extracellular Domain. This protein has a calculated molecular weight of 15 kDa. It has an apparent molecular weight of approximately 33-38 kDa by SDS-PAGE under reducing conditions due to glycosylation.



ACTRIIB Extracellular Domain (human, recombinant) (Item No. 44184) immobilized on CM5 chip can bind Recombinant Mouse Activin A Protein, His Tag with an affinity constant of 2.42 nM as determined in an SPR assay (Biacore 8K) (routinely tested).



WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.


Copyright Cayman Chemical Company, 01/08/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM


PRODUCT INFORMATION




Images



ACTRIIB Extracellular Domain (human, recombinant) (Item No. 44184) immobilized on CM5 chip, can bind Recombinant Human/Mouse/Rat/Cynomolgus/Rhesus Activin A/INHBA Protein with an affinity constant of 0.239 nM as determined in an SPR assay (Biacore 8K) (QC tested).



Measured by its ability to neutralize Activin-mediated inhibition on MPC11 cell proliferation. The ED_{50} for this effect is typically 0.3-2 µg/ml in the presence of 10 ng/ml recombinant Activin A (routinely tested).



Lot-to-lot consistency

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Activin receptor type IIB (ACTRIIB) is a type II activin receptor and member of the TGF- β receptor superfamily.^{1,2} It is composed of an extracellular ligand-binding domain, a transmembrane domain, an intracellular kinase domain, and a C-terminal tail.² ACTRIIB is ubiquitously expressed in fetal development with the highest expression in the brain and spinal cord and is enriched in adult skeletal muscle.^{3,4} ACTRIIB has several ligands, including activins, growth differentiation factor 8 (GDF8), also known as myostatin, and bone morphogenetic proteins (BMPs).² Upon ligand binding, ACTRIIB forms a complex with type I activin receptors, which results in their activation and signaling *via* the SMAD pathway. ACTRIIB is involved in hematopoiesis, myogenesis, and bone formation and resorption.⁵ Mutations in the gene encoding ACTRIIB, *ACVR2B*, are associated with left-right axis malformations.⁶ Formulations containing a fusion protein of the ACTRIIB ligand-binding domain with the Fc of an immunoglobulin have been used as erythroid maturation agents in the treatment of anemia in patients with β -thalassemia or myelodysplastic syndrome (MDS). Cayman's ACTRIIB Extracellular Domain (human, recombinant) protein can be used for binding assay and cell-based assay applications. This protein consists of 127 amino acids, has a calculated molecular weight of 15 kDa, and a predicted N-terminus of Ser19 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 33-38 kDa due to glycosylation.

References

1. Attisano, L., Wrana, J.L., Montalvo, E., *et al.* Activation of signalling by the activin receptor complex. *Mol. Cell. Biol.* **16**(3), 1066-1073 (1996).
2. Leung, P.C.K. and Peng, C. Activin Receptor Signaling. *Encyclopedia of Hormones* 17-23 (2003).
3. Hildén, K., Tuuri, T., Erämaa, M., *et al.* Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor. *Blood* **83**(8), 2163-2170 (1994).
4. Han, H.Q., Zhou, X., Mitch, W.E., *et al.* Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. *Int. J. Biochem. Cell Biol.* **45**(10), 2333-2347 (2013).
5. Lodberg, A. Principles of the activin receptor signaling pathway and its inhibition. *Cytokine Growth Factor Rev.* **60**, 1-17 (2021).
6. Kosaki, R., Gebbia, M., Kosaki, K., *et al.* Left-right axis malformations associated with mutations in *ACVR2B*, the gene for human activin receptor type IIB. *Am. J. Med. Genet.* **82**(1), 70-76 (1999).